Proteasome inhibitors: all 957 studies that test it
Page 7 of 10. Open to participants first (61), then studies with results posted, then the rest; newest registration first within each.
- Monitoring and Treatment of Relapsed Leukemia Following Allogeneic Hematopoietic Stem Cell Transplantation in ChildrenTerminatedNCT02484261Phase 1
- Relapse Myeloma; Cyclofosfamide; Bortezomib; MaintenanceCompletedNCT02467010Phase 2
- Phase II Randomised Trial of Cyclophosphamide & Dexamethasone in Combination With Ixazomib in Relapsed or Refractory Multiple Myeloma.CompletedNCT02461888Phase 2
- B-Cell Targeted Carfilzomib DesensitizationStatus unknownNCT02442648Phase 1
- Ixazomib Citrate With Gemcitabine Hydrochloride and Doxorubicin Hydrochloride in Treating Patients With Urothelial Cancer That is Metastatic or Cannot Be Removed by SurgeryActive, not recruitingNCT02420847Phase 1/2
- Carfilzomib in Treatment Patients Under 65 Years With High Risk Smoldering Multiple MyelomaActive, not recruitingNCT02415413Phase 2
- Ixazomib in Combination With Thalidomide - Dexamethasone in Patients With Relapsed and/or Refractory Multiple MyelomaCompletedNCT02410694Phase 2
- Trial Studying Maintenance Treatment With Lenalidomide and Dexamethasone Versus Lenalidomide, Dexamethasone and MLN9708 After Autologous Hematopoietic Stem Cell Transplantation in Patients With Newly-diagnosed Symptomatic Multiple MyelomaCompletedNCT02406144Phase 3
- Phase I Study of the Combination of MLN9708 and FulvestrantTerminatedNCT02384746Phase 1
- Combination of Ibrutinib and Bortezomib to Treat Patients With Mantle Cell LymphomaTerminatedNCT02356458Phase 1/2
- Bortezomib With Steroid Pulse Therapy for Acute Cellular Rejection in Kidney TransplantationStatus unknownNCT02351427Phase 3
- Velcade and Lenalidomide in Patients With Relapsed AML and MDS After Allogeneic Stem Cell TransplantationCompletedNCT02312102Phase 1
- Nonmyeloablative Allogeneic Stem Cell Transplant Followed by Bortezomib in High-risk Multiple Myeloma PatientsCompletedNCT02308280Phase 2
- Study of Carfilzomib Weekly Plus Melphalan and Prednisone in Untreated Symptomatic Elderly Multiple MyelomaCompletedNCT02302495Phase 2
- Carfilzomib and Hyper-CVAD in Treating Patients With Newly Diagnosed Acute Lymphoblastic Leukemia or LymphomaCompletedNCT02293109Phase 1
- Trial of PCI-32765 (BTK Inhibitor) in Combination With Carfilzomib in Relapse/Refractory Mantle Cell LymphomaTerminatedNCT02269085Phase 1
- A Pharmacokinetic Study of Bortezomib in Taiwanese Participants With Multiple MyelomaCompletedNCT02268890Phase 4
- Extended Infusion Carfilzomib on a Weekly Schedule in Patients With Advanced Solid TumorsCompletedNCT02257476Phase 1
- A Phase 1 Study of Oprozomib to Assess Food Effect, Drug-Drug Interaction With Midazolam, and Safety and Tolerability in Patients With Advanced MalignanciesTerminatedNCT02244112Phase 1
- Bendamustine, Prednisone and Velcade® for First-line Treatment of Patients With Symptomatic Multiple MyelomaCompletedNCT02237261Phase 2
- Phase I Study of MLN 9708 in Addition to Chemotherapy for the Treatment of Acute Lymphoblastic Leukemia in Older AdultsCompletedNCT02228772Phase 1
- Phase 1b/2 Study of Oprozomib in Combination With Sorafenib in Subjects With Advanced Hepatocellular CarcinomaWithdrawnNCT02227914Phase 1/2
- Phase I Study of Bortezomib With G-CSF for Stem Cell Mobilization in Patients With Multiple MyelomaCompletedNCT02220608Phase 1
- Dose Escalation of Velcade Daily Dose in Patients With Solid TumorsCompletedNCT02220049Phase 1
- Study of the Efficacy and Safety of RsqVD Combination Therapy for Patients With Newly Diagnosed Multiple MyelomaCompletedNCT02219178Phase 2
- Carfilzomib, Cyclophosphamide, Dexamethasone in Transplant Eligible Newly Diagnosed High-risk Multiple MyelomaCompletedNCT02217163Phase 2
- Trial of the Combination of Bortezomib and Clofarabine in Adults With Relapsed Solid TumorsCompletedNCT02211755Phase 1
- Study of Carfilzomib, Cyclophosphamide and Dexamethasone in Newly Diagnosed Multiple Myeloma PatientsCompletedNCT02204241Phase 1/2
- Bortezomib in Rejection of Kidney TransplantsCompletedNCT02201576Phase 2
- Nelfinavir as Bortezomib-sensitizing Drug in Patients With Proteasome Inhibitor-nonresponsive MyelomaCompletedNCT02188537Phase 2
- Carfilzomib With Bendamustine and Rituximab in Patients With Relapsed or Refractory Non-Hodgkin LymphomaCompletedNCT02187133Phase 1
- Phase I/II Study of Carfilzomib, Pomalidomide and Dexamethasone in Relapsed And/Or Refractory Multiple Myeloma Patients (CPD)CompletedNCT02185820Phase 1/2
- Velcade, Thalidomide, Dexamethasone and Panobinostat Treatment and Panobinostat Maintenance in Multiple MyelomaStatus unknownNCT02145715Phase 1/2
- Carfilzomib Plus Belinostat in Relapsed/Refractory NHLCompletedNCT02142530Phase 1
- Carfilzomib/SAHA Combined With High-Dose Gemcitabine/Busulfan/Melphalan With Autologous Stem Cell Transplant in MyelomaWithdrawnNCT02114502Phase 2
- Microdose Study of Melphalan, Bortezomib and DexamethasoneStatus unknownNCT02109861Early Phase 1
- Combination Study of Pomalidomide, Marizomib, and Low-Dose Dexamethasone in Relapsed and Refractory Multiple MyelomaCompletedNCT02103335Phase 1
- Therapy of Antibody-mediated Autoimmune Diseases by Bortezomib (TAVAB)TerminatedNCT02102594Phase 2
- Carfilzomib, Bendamustine Hydrochloride, and Dexamethasone in Treating Patients With Relapsed or Refractory Multiple MyelomaCompletedNCT02095834Phase 1
- Tolerability and Efficacy of Modified VCD Regimens in Previously Untreated Multiple Myeloma.Status unknownNCT02086942Phase 2
- Bortezomib, Dexamethasone, and Cyclophosphamide in Treating Older Patients With Multiple MyelomaWithdrawnNCT02082405Phase 2
- A Study of Oprozomib, Melphalan, and Prednisone in Transplant Ineligible Patients With Newly Diagnosed Multiple MyelomaCompletedNCT02072863Phase 1/2
- Ixazomib, Mitoxantrone Hydrochloride, Etoposide, and Intermediate-Dose Cytarabine in Relapsed or Refractory Acute Myeloid LeukemiaCompletedNCT02070458Phase 1
- Carfilzomib In Combination With Bendamustine And Dexamethasone In Refractory Or Relapsed Multiple MyelomaCompletedNCT02056756Phase 1/2
- MLN9708 and Vorinostat in Patients With Advanced p53 Mutant MalignanciesCompletedNCT02042989Phase 1
- Combination of G-CSF, Bortezomib, Cyclophosphamide and Dexamethasone in Patients With Multiple MyelomaStatus unknownNCT02027220Phase 2
- Bortezomib Maintenance in High Risk DLBCLStatus unknownNCT01965977Phase 2
- A Phase I Study Of Panobinostat/Lenalidomide/Bortezomib/Dex for Relapsed And Relapsed/Refractory Multiple MyelomaCompletedNCT01965353Phase 1
- Lenalidomide After Donor Stem Cell Transplant and Bortezomib in Treating Patients With High Risk Multiple MyelomaTerminatedNCT01954784Phase 1
- Proteasome Inhibition in Acute Promyelocytic LeukemiaStatus unknownNCT01950611Phase 2
- Safety and Efficacy Study of a Triplet Combination of MLN9708, Lenalidomide and Dexamethasone in the Initial Management of Multiple Myeloma (IFM2013-06)CompletedNCT01936532Phase 2
- Bortezomib, Melphalan, and Total-Body Irradiation Before Stem Cell Transplant in Treating Patients With Multiple MyelomaCompletedNCT01936090Phase 1
- Carfilzomib Consolidation Therapy After Autologous Stem Cell Transplantation (ASCT) for Mantle Cell Lymphoma (MCL), T-cell Lymphoma (TCL), and Diffuse Large B-Cell Lymphoma (DLBCL)CompletedNCT01926665Phase 1
- Maintenance Therapy With Subcutaneous BortezomibCompletedNCT01913730Phase 2
- Study to Evaluate Optimized Retreatment and Prolonged Therapy With BortezomibCompletedNCT01910987Phase 3
- An Efficacy and Tolerability Study of Bortezomib in Combination With Rituximab Standard Therapy in Participants With Relapsed or Refractory Follicular LymphomaTerminatedNCT01902862Phase 2
- Bortezomib in Late Antibody-mediated Kidney Transplant RejectionCompletedNCT01873157Phase 2
- Proteasomal Inhibition for Patients With Mis-sense Mutated DysferlinTerminatedNCT01863004Phase 1
- Bortezomib, Sorafenib Tosylate, and Decitabine in Treating Patients With Acute Myeloid LeukemiaActive, not recruitingNCT01861314Phase 1
- Study of Weekly Carfilzomib, Cyclophosphamide and Dexamethasone In Newly Diagnosed Multiple Myeloma Patients (wCCyd)CompletedNCT01857115Phase 1/2
- Efficacy/Safety Study of R-CHOP vs Bortezomib-R-CAP for Young Patients With Diffuse Large B-cell Lymphoma With Poor IPI.CompletedNCT01848132Phase 2
- Desensitization With Bortezomib Before a Living Kidney DonationStatus unknownNCT01842074Phase 4
- VELCADE® Plus Rituximab in Non Hodgkin's Follicular LymphomaCompletedNCT01830465Phase 2
- Carfilzomib and Dexamethasone in Treating Patients With Multiple Myeloma Who Previously Underwent a Stem Cell TransplantWithdrawnNCT01812720Phase 2
- Safety, Efficacy, and Pharmacodynamics of a 60-Minute Infusion of Carfilzomib for Progressive Multiple MyelomaStatus unknownNCT01792102Phase 1/2
- A Safety Study of Carfilzomib in Patients With Previously-Treated Systemic Light Chain AmyloidosisCompletedNCT01789242Phase 1
- Efficacy of First Line DRC +/- Bortezomib for Patients With Waldenström's MacroglobulinemiaCompletedNCT01788020Phase 3
- Phase I/II Carfilzomib Plus Lenalidomide and Rituximab in the Treatment of Relapsed/Refractory Mantle Cell LymphomaTerminatedNCT01729104Phase 1
- First-line Pomalidomide, Bortezomib, and Dexamethasone For AL Amyloidosis or LCDDTerminatedNCT01728259Phase 1
- Vorinostat, Bortezomib and Dexamethasone in Multiple Myeloma (MUKFour)CompletedNCT01720875Phase 2
- Short Course of Bortezomib in Anemic Patients With Refractory Cold Agglutinin DiseaseCompletedNCT01696474Phase 2
- Lenalidomide, Adriamycin, Dexamethasone (RAD) Versus Lenalidomide, Bortezomib, Dexamethasone (VRD) for Induction in Newly Diagnosed Multiple Myeloma Followed by Response-adapted Consolidation and Lenalidomide MaintenanceStatus unknownNCT01685814Phase 3
- Dovitinib Combined With Bortezomib and Dexamethasone for Relapsed/Refractory Multiple MyelomaWithdrawnNCT01680796Phase 1
- Bortezomib in Patients With Chronic Graft Versus Host DiseaseCompletedNCT01672229Phase 1
- Carfilzomib, Pomalidomide, and Dexamethasone in Treating Patients With Relapsed or Refractory Multiple MyelomaCompletedNCT01665794Phase 1/2
- MLN9708 and Dexamethasone for High-Risk Smoldering Multiple MyelomaWithdrawnNCT01660997Phase 2
- A Safety Study of Carfilzomib, Cyclophosphamide & Dexamethasone Prior to ASCT in Patients With Newly Diagnosed MyelomaCompletedNCT01660750Phase 1
- Phase II Study of Subcutaneous (SC) Bortezomib, Lenalidomide and Dexamethasone for Relapsed and/or Refractory Multiple Myeloma; Followed by SC Bortezomib MaintenanceWithdrawnNCT01647165Phase 2
- Bortezomib in Combination With Gemcitabine and Cisplatin in Advanced or Metastatic Non-Small Cell Lung CancerCompletedNCT01633645Phase 2
- Autophagy Induction After Bortezomib for MyelomaCompletedNCT01594242Early Phase 1
- Randomised Trial in Waldenstrom's MacroglobulinaemiaCompletedNCT01592981Phase 2
- Study of the Combination of Panobinostat & Carfilzomib in Patients With Relapsed &/or Refractory Multiple MyelomaCompletedNCT01549431Phase 1
- Filgrastim in Treating Patients With Bortezomib-, Carfilzomib-, or IMID-Refractory Multiple MyelomaTerminatedNCT01537861Early Phase 1
- Lenalidomide and Low Dose Dexamethasone Versus Bortezomib, Lenalidomide and Low Dose Dexamethasone for Induction, in Patients With Previously Untreated Multiple MyelomaCompletedNCT01530594Phase 3
- Bortezomib Consolidation TrialCompletedNCT01517724Phase 2
- Lapatinib and Bortezomib in Patients With Advanced MalignanciesTerminatedNCT01497626Phase 1
- Study of Vorinostat With Doxil and Bortezomib for Patients With Relapsed/Refractory Multiple MyelomaWithdrawnNCT01492881Phase 2
- ACVDL Treatment for Patients With Newly Diagnosed Multiple MyelomaCompletedNCT01481194Phase 2
- A Safety and Efficacy Study of Carfilzomib and Pomalidomide With Dexamethasone in Patients With Relapsed or Refractory Multiple MyelomaTerminatedNCT01464034Phase 1/2
- Sequential Trial on Reduced Intensity Conditioning (RIC) Allogeneic TransplantationCompletedNCT01460420Phase 1/2
- Efficacy and Safety of R-HAD Alone or in Combination With Bortezomib in Patients With Relapsed or Refractory MCLStatus unknownNCT01449344Phase 3
- Radiation Therapy and Bortezomib and Cetuximab With or Without Cisplatin to Treat Head and Neck CancerCompletedNCT01445405Phase 1
- Combination Therapy of Lenalidomide/Bortezomib/Dexamethasone and Panobinostat in Transplant Eligible New Diagnosed Multiple Myeloma (MM) PatientsCompletedNCT01440582Phase 1
- Bortezomib (VELCADE), Cladribine and Rituximab (VCR) in Mantle Cell Lymphoma (PSHCI 10-011)Status unknownNCT01439750Phase 1
- Trial of Temozolomide, Bevacizumab Plus Bortezomib for Recurrent Glioblastoma MultiformeCompletedNCT01435395Phase 1
- Open-label Study of the Safety and Activity of Oprozomib in Patients With Hematologic MalignanciesTerminatedNCT01416428Phase 1/2
- Clonal Deletion on Living-Relative Donor Kidney TransplantationStatus unknownNCT01408797Phase 1/2
- Vorinostat in Combination With Bortezomib, Doxorubicin and Dexamethasone (VBDD) in Patients With Refractory or Relapsed Multiple Myeloma (MM)CompletedNCT01394354Phase 1/2
- Vorinostat With or Without Bortezomib in Treating Patients With Refractory or Recurrent Stage IIB, Stage III, or Stage IV Cutaneous T-Cell LymphomaWithdrawnNCT01386398Phase 3
- Bendamustine, Bortezomib (Velcade ®) and Prednisone (BVP) in Patients Newly Diagnosed Multiple MyelomaCompletedNCT01376401Phase 2